Trial Profile
A Phase 2 Study of the IDH1 Inhibitor, IDH305, for the Treatment of IDH1 Mutated Low Grade Glioma Patients Who Have Measurable 2HG by MR Spectroscopy
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs IDH 305 (Primary)
- Indications Glioma
- Focus Therapeutic Use
- 09 Oct 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 13 Dec 2016 New trial record